▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / NBIX

NBIX — NEUROCRINE BIOSCIENCES INC

—
Nasdaq · Health Care · Biotechnology · CIK 914475 ·
Last close
$159.76
Market Cap
$16.06B
52W High
$169.57
52W Low
$125.11
ADV30
1,238,390
Next earnings
2026-07-29
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 814,500,000 800,700,000 186,000,000 197,900,000 4,906,200,000 266,500,000 1,498,800,000
Dec 2025 805,500,000 787,900,000 227,900,000 153,700,000 4,631,500,000 713,000,000 1,378,400,000
Sep 2025 794,900,000 780,900,000 239,300,000 209,500,000 4,265,700,000 340,200,000 1,262,100,000
Jun 2025 687,500,000 676,200,000 145,600,000 107,500,000 3,889,800,000 264,000,000 1,195,500,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$863,700,000
Investing CF
$-784,800,000
Financing CF
$-6,500,000
CapEx
$-45,500,000
Dividends Paid
—
Buybacks
$-71,700,000
EPS Diluted TTM
$6.49
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$589,600,000
Inventory
$64,500,000
Receivables
$768,100,000
ST Investments
$1,049,700,000
EBIT TTM
$798,800,000
Pretax Income TTM
$937,500,000
Interest Exp TTM
—
Analysts
27

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,102,400,000
EBITDA
$828,600,000
Free Cash Flow
$590,550,016
Enterprise Value
$15,211,165,696
Total Cash
$1,316,199,936
Total Debt
$463,500,000
Shares Out
100,549,983
Trailing EPS
$6.50
Book Value
$33.87
ROE
22.5%
ROA
11.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,860,500,000 636,500,000 478,600,000 4,631,500,000 1,378,400,000 — 782,700,000
Dec 2024 2,355,300,000 583,000,000 341,300,000 3,718,700,000 1,129,000,000 — 595,400,000
Dec 2023 1,887,100,000 394,800,000 249,700,000 3,251,400,000 1,019,400,000 — 389,900,000
Dec 2022 1,488,700,000 249,000,000 154,500,000 2,368,700,000 660,900,000 — 339,400,000

TTM Snapshot

Revenues TTM
$1,804,800,000
NetIncome TTM
$303,900,000
OpCashFlow TTM
$0
Assets (Latest)
$3,718,700,000
Forward EPS
$12.71

Max Pain — expiry 2026-12-18

max pain strike: $160.00 · spot: $159.51 · call oi: 654 · put oi: 2,704
Expected Move to 2026-12-18: ±$46.55 (29.18%) — implied range $112.96 – $206.06 · ATM straddle on $160.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EXEL EXELIXIS, INC. $13.35B $53.13 —
MRNA Moderna, Inc. $19.80B $49.91 —
BNTX BioNTech SE $22.90B $90.54 —
KRYS Krystal Biotech, Inc. $9.37B $317.97 —
BIIB BIOGEN INC. $29.53B $200.05 —

News headlines (Yahoo Finance, 1h cache)

Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Follo
2026-06-15 20:10 · Yahoo
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
2026-06-15 20:05 · Yahoo
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?
2026-06-15 14:55 · Yahoo
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
2026-06-15 12:35 · Yahoo
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
2026-06-15 12:30 · Yahoo
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patient
2026-06-08 20:05 · Yahoo
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Deve
2026-06-08 12:30 · Yahoo
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum
2026-06-05 04:50 · Yahoo
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)
2026-06-04 16:49 · Yahoo
Dow Jones Futures Rise, But Broadcom, CrowdStrike, Ciena Hit Techs; SpaceX IPO Price Target Set
2026-06-04 12:06 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →